- Home
- DNLI
as 11-15-2024 4:00pm EST
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 4.5B | IPO Year: | 2017 |
| Target Price: | $38.90 | AVG Volume (30 days): | 788.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.56 - $33.33 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | 204.74% |
| Revenue Growth (this year): | -94.69% | Revenue Growth (next year): | 283.75% |
Stock Insider Trading Activity of Denali Therapeutics Inc. (DNLI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schuth Alexander O. | DNLI | COFO and Secretary | Nov 7 '24 | Sell | $30.56 | 15,558 | $465,286.44 | 181,291 | |
| SATO VICKI L | DNLI | Director | Nov 7 '24 | Sell | $30.00 | 1,020 | $30,600.00 | 111,056 | |
| SATO VICKI L | DNLI | Director | Nov 1 '24 | Sell | $27.07 | 3,080 | $83,375.60 | 111,056 | |
| Watts Ryan J. | DNLI | President and CEO | Oct 18 '24 | Sell | $27.69 | 40,000 | $1,107,600.00 | 235,807 | |
| Krognes Steve E. | DNLI | Director | Sep 30 '24 | Sell | $29.03 | 30,000 | $870,900.00 | 29,096 | |
| SATO VICKI L | DNLI | Director | Sep 13 '24 | Sell | $30.00 | 1,020 | $30,600.00 | 111,056 | |
| SATO VICKI L | DNLI | Director | Sep 3 '24 | Sell | $25.18 | 3,080 | $77,007.20 | 111,056 | |
| Krognes Steve E. | DNLI | Director | Aug 20 '24 | Sell | $23.79 | 1,727 | $41,085.33 | 29,096 | |
| Watts Ryan J. | DNLI | President and CEO | Aug 20 '24 | Sell | $23.79 | 2,260 | $53,765.40 | 235,807 | |
| Schuth Alexander O. | DNLI | COFO and Secretary | Aug 20 '24 | Sell | $24.04 | 8,353 | $200,401.15 | 181,291 |
Latest Denali Therapeutics Inc. News
DNLI Breaking Stock News: Dive into DNLI Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
MT Newswires
4 days ago
Denali Therapeutics Insider Sold Shares Worth $1,932,665, According to a Recent SEC Filing
Zacks
9 days ago
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
GlobeNewswire
11 days ago
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Zacks
18 days ago
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for
Zacks
19 days ago
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
MT Newswires
a month ago
Denali Therapeutics Insider Sold Shares Worth $1,107,600, According to a Recent SEC Filing
Insider Monkey
a month ago
Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now
Compare DNLI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DNLI Denali Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.